NCT04976803
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ATM
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic, uncontrolled brain metastases or leptomeningeal disease that require treatment; Patients with previous treatment targeting the ATR/CHK1 pathway
https://ClinicalTrials.gov/show/NCT04976803